Advancements in longevity pharmacology research - are we finally seeing clinical progression?
Level 5 - mechanism / opinion, no new human data
Narrative review and expert perspective without systematic quantitative synthesis or new human data
PubMed 42397379 · doi:10.1080/13543784.2026.2698526
What was done
The authors conducted a narrative literature review searching PubMed/MEDLINE, Scopus, and Web of Science for English-language publications from January 2000 to April 2026. They assessed progress across senescence biology, autophagy/mitophagy, metabolic pathways, stem cells, natural products, microbiome targets, systemic chronic inflammation, and AI-enabled biomarker development.
What was found
The abstract reports no numerical findings or effect sizes. The authors found that although mechanistic understanding has advanced rapidly, most gerotherapeutic interventions remain in preclinical stages or lack long-term clinical validation. Key translational bottlenecks include biomarker deficits, biological heterogeneity, safety concerns, regulatory misalignment, and limitations inherent to animal models.
Why it matters
It provides a realistic assessment of the translational gap in geroscience, emphasizing that near-term clinical success will likely rely on low-risk, system-level approaches paired with validated aging biomarkers rather than immediate radical rejuvenation.
Limits
As a narrative review, it lacks systematic search criteria, quality scoring of included studies, quantitative pooling, or new human empirical data. The total number of reviewed studies is not reported in the abstract.
Cited by
- supports There are no human interventions tested or validated that have been shown to extend lifespan.